Accueil › Annuaire des chercheurs › John N. Gitonga
John N. Gitonga
Affiliation : Kenya Medical Research Institute · KEMRI-Wellcome Trust Research Programme
- 29Publications (affiliation kényane)
Profil de recherche
John N. Gitonga compte 29 publications référencées (2019–2026). Ses travaux paraissent principalement dans « Wellcome Open Research », « BMC Infectious Diseases » et « The Lancet Infectious Diseases ». Son article le plus cité, « Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors » (2020), a été cité 328 fois. 4 de ces publications datent des trois dernières années d’activité. Ses travaux sont cosignés avec au moins 12 chercheurs, notamment dans des établissements de Royaume-Uni, Brésil, États-Unis, Allemagne.
C’est vous ? Faites connaître vos travaux
Créez gratuitement votre profil DzCademia et ajoutez vos articles : ils apparaîtront plus facilement sur Google et dans les assistants d’IA comme ChatGPT. Plus de personnes pourront vous lire et vous citer.
Créer mon profil gratuit Ajouter mes publicationsPublications (29)
- Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial
- Low-Dose Yellow Fever Vaccine in Adults in Africa
- Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024
- Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya
- Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
- SARS‐CoV‐2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February–December 2022
- Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial
- Validation of saline, PBS and a locally produced VTM at varying storage conditions to detect the SARS-CoV-2 virus by qRT-PCR
- Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
- SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021
- Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020–21
- Incidence of chikungunya virus infections among Kenyan children with neurological disease, 2014–2018: A cohort study
- Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya
- Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
- COVID-19 transmission dynamics underlying epidemic waves in Kenya
- Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya
- Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021
- Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya
- Endemic chikungunya fever in Kenyan children: a prospective cohort study
- Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya
- Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels
- Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations
- Pooled testing conserves SARS-CoV-2 laboratory resources and improves test turn-around time: experience on the Kenyan Coast
- Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
- Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein
- An optimisation of four SARS-CoV-2 qRT-PCR assays in a Kenyan laboratory to support the national COVID-19 rapid response teams
- Pooled testing conserves SARS-CoV-2 laboratory resources and improves test turn-around time: experience on the Kenyan Coast
- Congenital microcephaly unrelated to flavivirus exposure in coastal Kenya
- Complete Genome Sequences of Dengue Virus Type 2 Strains from Kilifi, Kenya
Revues de publication
- Wellcome Open Research × 6
- BMC Infectious Diseases × 2
- The Lancet Infectious Diseases × 2
- PLoS ONE × 2
- Science × 2
- Nature Communications × 2
Publications par année
- 20261
- 20252
- 20241
- 20235
- 20225
- 20219
- 20204
- 20192
Collaborations
Établissements partenaires : University of Oxford · Ministry of Health · London School of Hygiene & Tropical Medicine · Wellcome Trust · Government of Kenya
Pays des co-auteurs : Royaume-Uni · Brésil · États-Unis · Allemagne
Co-auteurs
- George M. Warimwe
- Henry Karanja
- Daisy Mugo
- Philip Bejon
- Lynette Isabella Ochola‐Oyier
- Charles N. Agoti
- James Nyagwange
- Ambrose Agweyu
- Benjamin Tsofa
- Mark Otiende
- J. Anthony G. Scott
- Ifedayo Adetifa
Données bibliographiques issues d’OpenAlex (base ouverte).
Pourquoi choisir Dzcademia ?
Pour donner à vos travaux plus de chances d’être découverts et recommandés par les IA. Profils, articles et communications : donnez à votre recherche une présence publique structurée. Les métadonnées intégrées aident les moteurs de recherche et les assistants IA à identifier vos travaux et à comprendre leurs références.
Commenter avec Google
Connecte-toi avec Google pour commenter directement sur cette page.